Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DURHAM, N.C., Feb. 22, 2016 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, February 29, 2016 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2015, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 51992168. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
